[F:1][C:2]1[CH:3]=[C:4]([N:14]2[CH2:18][C@H:17]([CH2:19]O)[O:16][C:15]2=[O:21])[CH:5]=[CH:6][C:7]=1[N:8]1[CH:12]=[C:11]([CH3:13])[N:10]=[N:9]1.C(N(CC)CC)C.[CH3:29][S:30](Cl)(=[O:32])=[O:31].C(=O)(O)[O-].[Na+]>ClCCl>[F:1][C:2]1[CH:3]=[C:4]([N:14]2[CH2:18][C@H:17]([CH2:19][S:30]([CH3:29])(=[O:32])=[O:31])[O:16][C:15]2=[O:21])[CH:5]=[CH:6][C:7]=1[N:8]1[CH:12]=[C:11]([CH3:13])[N:10]=[N:9]1(5R)-3-[3-Fluoro-4-(4-methyl-1H-1,2,3-triazol-1-yl)phenyl]-5-(hydroxymethyl)oxazolidin-2-one (Intermediate 19) (4.0 g, 13.7 mmol) was dissolved in dichloromethane (30 ml) and cooled to 0° C. Triethylamine (3.08 ml, 23.3 mmol) was added, followed by methylsulfonyl chloride (1.27 ml, 16.4 mmol). It was stirred for one hour and poured into saturated aqueous sodium bicarbonate solution and diluted with dichloromethane (200 ml). The organic phase was dried over magnesium sulfate and solvent was removed under reduced pressure to give the title product (5.1 g) as a solid, which was used without further purification.
Loading…